ARS Pharmaceuticals, Inc (SPRY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $360.90M
Last updated: Nov 17, 2026 at 4:15 PM ET
ARS Pharmaceuticals, Inc (SPRY) Statistics
ARS Pharmaceuticals (SPRY) has a market cap of $360.90M and an enterprise value of $457.08M. It kept -163.64% of revenue as net income over the last 12 months. Revenue fell 14.45% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 26.65% above the market cap, as debt exceeds cash.
| Market Cap | $360.90M |
|---|---|
| Enterprise Value | $457.08M |
| Latest price (Nov 17, 2026) | $3.65 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.0x. Its year-end P/S ranged from 11.6x to 292.8x from 2021 to 2025.
| P/S Ratio | 3.0x |
|---|---|
| Forward P/S | 3.0x |
Price Statistics
The stock is down 55.54% over 52 weeks and trades 8.75% below its 50-day average.
| Beta (1Y) | 1.80 |
|---|---|
| 52-Week Change | -55.54% |
| 1-Month Change | -13.71% |
| 3-Month Change | -42.79% |
| 6-Month Change | -49.09% |
| 5-Year Change | -60.83% |
| Total Return (1Y) | -55.54% |
| Total Return (3Y CAGR) | -8.15% |
| Total Return (5Y CAGR) | -14.79% |
| Return vs SPY (1Y) | -60.04% |
| Max Drawdown (1Y) | -79.71% |
| Max Drawdown (3Y) | -85.56% |
| Sharpe Ratio (1Y) | -0.85 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $4.00 |
| 200-Day Average | $6.97 |
| 52-Week Range | $2.44 to $13.15 |
| RSI (14 Days) | 48.5 |
| Average Volume (20 Days) | 2.36M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.25x current liabilities.
| Current Ratio | 3.25x |
|---|---|
| Quick Ratio | 3.07x |
Returns and Efficiency
Return on invested capital is -143.84% over the last 12 months, against a 5-year average of -5.68%.
| Return on Assets (ROA) | -79.48% |
|---|---|
| Return on Invested Capital (ROIC) | -143.84% |
| ROA (5Y Average) | -23.72% |
| ROIC (5Y Average) | -5.68% |
| Asset Turnover | 0.39x |
| Inventory Turnover | 2.40x |
| Receivables Turnover | 2.45x |
| Cash Conversion Cycle | -501 days |
Scores
SPRY has an Altman Z-Score of -3.14, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.14 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $122.14M over the last 12 months.
| Revenue | $122.14M |
|---|---|
| Revenue Growth (YoY) | -14.45% |
| Gross Profit | $94.00M |
| Operating Income | -$197.25M |
| Pretax Income | -$196.71M |
| Net Income | -$199.87M |
| Reported EPS (TTM) | -$2.02 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $25.62M |
|---|---|
| Total Debt | $121.81M |
| Net Debt | $96.19M |
| Net Debt Per Share | $0.96 |
| Working Capital | $146.13M |
| Shareholder Equity | -$11.96M |
| Tangible Book Value | -$25.58M |
| Total Assets | $251.48M |
| Total Liabilities | $263.44M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$183.07M |
|---|---|
| FCF Per Share | -$1.84 |
| Depreciation and Amortization | $4.72M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -161.50%.
| Gross Margin | 76.96% |
|---|---|
| Operating Margin | -161.50% |
| Pretax Margin | -161.06% |
| Net Margin | -163.64% |
| Gross Margin (5Y Average) | 99.78% |
Growth
Revenue grew 300.09% a year over 3 years.
| Revenue Growth (3Y CAGR) | +300.09% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -30.51% |
| Tangible Book Per Share Growth (2Y CAGR) | -35.05% |
Dividends and Yields
SPRY does not pay a dividend.
| Buyback Yield | -1.43% |
|---|---|
| Shareholder Yield | -1.43% |
Peer Position
Against 7 similar companies, SPRY has the 6th highest P/S.
P/S RatioPeer median 4.3x
ROICPeer median -6.52%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +0.70%
| P/S Ratio | 3.0x vs 4.3x median |
|---|---|
| ROIC | -143.84% vs -6.52% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -14.45% vs +0.70% median |
Analyst Forecast
Consensus estimates put revenue growth at 42.06% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +42.06% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SPRY
What is SPRY's market cap?
ARS Pharmaceuticals has a market cap of $360.90M. Its enterprise value, which adds debt and subtracts cash, is $457.08M.
How many shares of SPRY are outstanding?
ARS Pharmaceuticals has 99.69M shares outstanding. The count is up 0.89% from a year earlier.
Does SPRY pay a dividend?
No. ARS Pharmaceuticals does not pay a dividend.
How much debt does SPRY have?
ARS Pharmaceuticals has $121.81M of total debt and $25.62M of cash and equivalents, a net debt position of $96.19M.
SPRY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors